| A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer A Potti, S Mukherjee, R Petersen, HK Dressman, A Bild, J Koontz, ... New England Journal of Medicine 355 (6), 570-580, 2006 | 701 | 2006 |
| Human lung carcinomas express Fas ligand GA Niehans, T Brunner, SP Frizelle, JC Liston, CT Salerno, DJ Knapp, ... Cancer research 57 (6), 1007-1012, 1997 | 541 | 1997 |
| Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. GA Otterson, RA Kratzke, A Coxon, YW Kim, FJ Kaye Oncogene 9 (11), 3375-3378, 1994 | 503 | 1994 |
| The pathogenesis of mesothelioma M Carbone, RA Kratzke, JR Testa Seminars in oncology 29 (1), 2-17, 2002 | 492 | 2002 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 429 | 2013 |
| Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer BA Whitson, RS Andrade, A Boettcher, R Bardales, RA Kratzke, ... The Annals of thoracic surgery 83 (6), 1965-1970, 2007 | 414 | 2007 |
| Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung … FA Shepherd, C Domerg, P Hainaut, PA Jänne, JP Pignon, S Graziano, ... Journal of clinical oncology 31 (17), 2173-2181, 2013 | 365 | 2013 |
| Prognostic effect of tumor lymphocytic infiltration in resectable non–small-cell lung cancer E Brambilla, G Le Teuff, S Marguet, S Lantuejoul, A Dunant, S Graziano, ... Journal of clinical oncology 34 (11), 1223, 2016 | 332 | 2016 |
| Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB … PA Jänne, X Wang, MA Socinski, J Crawford, TE Stinchcombe, L Gu, ... Journal of clinical oncology 30 (17), 2063, 2012 | 332* | 2012 |
| Rb and p16INK4a Expression in Resected Non-Small Cell Lung Tumors RA Kratzke, TM Greatens, JB Rubins, MA Maddaus, DE Niewoehner, ... Cancer research 56 (15), 3415-3420, 1996 | 330 | 1996 |
| Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B R Govindan, RA Kratzke, JE Herndon, GA Niehans, R Vollmer, D Watson, ... Clinical Cancer Research 11 (6), 2300-2304, 2005 | 309 | 2005 |
| Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16INK4A in Archival … J Geradts, RA Kratzke, GA Niehans, CE Lincoln Cancer research 55 (24), 6006-6011, 1995 | 290 | 1995 |
| Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection MS Tsao, S Marguet, G Le Teuff, S Lantuejoul, FA Shepherd, L Seymour, ... Journal of clinical oncology 33 (30), 3439, 2015 | 286 | 2015 |
| A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. FJ Kaye, RA Kratzke, JL Gerster, JM Horowitz Proceedings of the National Academy of Sciences 87 (17), 6922-6926, 1990 | 277 | 1990 |
| Tumor mutation burden as a biomarker in resected non–small-cell lung cancer S Devarakonda, F Rotolo, MS Tsao, I Lanc, E Brambilla, A Masood, ... Journal of Clinical Oncology 36 (30), 2995, 2018 | 235 | 2018 |
| Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma R Jagadeeswaran, PC Ma, TY Seiwert, S Jagadeeswaran, O Zumba, ... Cancer research 66 (1), 352-361, 2006 | 230 | 2006 |
| Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non–small-cell lung cancer … R Govindan, J Bogart, T Stinchcombe, X Wang, L Hodgson, R Kratzke, ... Journal of clinical oncology 29 (23), 3120, 2011 | 222 | 2011 |
| Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+ chemotherapy-Cancer and Leukemia Group B Trial 30203 MJ Edelman, D Watson, X Wang, C Morrison, RA Kratzke, S Jewell, ... Journal of Clinical Oncology 26 (6), 848-855, 2008 | 205 | 2008 |
| Epigenetics of lung cancer SM Langevin, RA Kratzke, KT Kelsey Translational Research 165 (1), 74-90, 2015 | 199 | 2015 |
| Immunohistochemical Analysis of the p16INK4 Cyclin-Dependent Kinase Inhibitor in Malignant Mesothelioma RA Kratzke, GA Otterson, CE Lincoln, S Ewing, H Oie, J Geradts, FJ Kaye JNCI: Journal of the National Cancer Institute 87 (24), 1870-1875, 1995 | 172 | 1995 |
